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Mechanism-of-action (MOA) studies of bioactive
compounds are fundamental to drug discovery.
However, in vitro studies alone may not recapit-
ulate a compound’s MOA in whole cells. Here,
we apply a chemogenomics approach in Can-
dida albicans to evaluate compounds affecting
purine metabolism. They include the IMP dehy-
drogenase inhibitors mycophenolic acid and
mizoribineand thepreviously reportedGMPsyn-
thase inhibitors acivicin and 6-diazo-5-oxo-L-
norleucine (DON). We report important aspects
of their whole-cell activity, including their pri-
mary target, off-target activity, and drug metab-
olism. Further, we describe ECC1385, an inhibi-
tor of GMP synthase, and provide biochemical
and genetic evidence supporting its MOA to
be distinct from acivicin or DON. Importantly,
GMP synthase activity is conditionally essential
in C. albicans and Aspergillus fumigatus and is
required for virulence of both pathogens, thus
constituting an unexpected antifungal target.
INTRODUCTION
Improving methods to identify bioactive small molecules
and their cognate protein targets remains an important
challenge. Traditionally, target-specific inhibitors have
been identified by using in vitro biochemical screens and
their mechanisms of action (MOAs) verified in the cellular
milieu by genetic means. An expanding repertoire of new
approaches to study small-molecule MOAs includes
transcriptional profiling, protein-chip arrays, as well as
multiple proteomics-based techniques [1–3]. More re-
cently, small-molecule microarrays [4, 5], and a variety
of phenotype-based chemical genomics strategies [6]
have emerged. Typically, such approaches are developedChemistry & Biology 14, 1163–11with model organisms, thus providing generic strategies
toward compound MOA determination. However, in par-
ticular instances (e.g., anti-infective drug discovery), MOA
analyses could be refined by customizing such strategies
so they may be performed within specific pathogens of
clinical relevance.
A prominent chemical-genetics-based approach to
MOAdetermination inSaccharomyces cerevisiae is termed
the Fitness Test (FT) [7, 8]. This assay relies on the principle
that heterozygosity of a given gene in a diploid can sen-
sitize the resultant strain to the cognate inhibitor of the
corresponding protein [9]. Assays based on this phenome-
non, known as chemically induced haploinsufficiency
(HI), when performed across a genome-wide collection of
heterozygous deletion mutants, provide important mecha-
nistic clues relating to the inhibitory action of small mole-
cules [7, 8, 10]. Moreover, by introducing strain-identifying
barcodes into each heterozygote mutant, the complete
strain collection may be rapidly screened en masse in the
presence and absence of compound, and the difference
in growth of individual strains subsequently inferred by
microarray analysis of all barcodes. The profiles of individ-
ual mutants that display compound-specific growth effects
(i.e., altered fitness) typically correspond to the inhibitor’s
cellular target, metabolism, uptake, or efflux.
Recently, we have adapted the FT approach to C. albi-
cans [11], the primary fungal pathogen of medical impor-
tance [12, 13].Genes represented in theC.albicansFitness
Test (CaFT) include those: (1) experimentally demon-
strated as essential in S. cerevisiae [14] and/or C. albicans
[15], (2) broadly conserved in A. fumigatus, and/or (3) shar-
ing strong homology to genes conserved in metazoans
[11]. Here, we apply the CaFT assay to identify the molec-
ular target of ECC1385, an antifungal compound, as being
guanosine 50-monophosphate synthase (GMPS, encoded
by GUA1) and mechanistically characterize this molecule
in relation to other known inhibitors affecting nucleotide
metabolism. Consistent with genetic studies, in vitro bio-
chemical data verify ECC1385 acts as a potent inhibitor
of Gua1. Intriguingly, although a gua1 loss-of-function75, October 2007 ª2007 Elsevier Ltd All rights reserved 1163
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Nucleotide Synthesis Inhibitors in C. albicansFigure 1. CaFT Profiling of ECC1385, MPA, and MZ and Verification of Strain Sensitivities
(A) ECC1385 structure.
(B) CaFT profiling of ECC1385, MPA, andMZ. Significant heterozygous strain depletions are noted (see text for details); small gray circles represent all
other strains within the CaFT assay. Compound concentrations used and the corresponding fitness values (F) obtained are shown; the F value is the
fraction of the cell growth attained in the presence of the indicated drug concentration versus untreated cells (e.g., F = 1 reflects no drug inhibitory
effect on growth; F = 0.15 reflects drug treated cells reached 15% of the OD of the control culture). Positive z-score values indicate hypersensitivity to
compound treatment, and negative z-score values indicate resistance. For a detailed explanation of z-score calculations, see [11].
(C) MIC determinations of ECC1385. Select heterozygote strains are indicated. TheHIS3 strain is the congenic parent of all heterozygous strains used
in this study. Growth has been determined by reading culture OD600 and comparing against the untreated culture.
(D) MIC determinations of MPA. Select heterozygote strains are indicated.mutant is suppressed by exogenous guanine in cultures,
GMPS activity is essential for the pathogenicity of C. albi-
cans as well as A. fumigatus, the second medically signifi-
cant fungal pathogen [16]. Unlike ECC1385, other structur-
ally distinct GMPS inhibitors examined such as acivicin
(ACI) and 6-diazo-5-oxo-L-norleucine (DON) do not signif-
icantly induce hypersensitivity of the GUA1 heterozygote
but likely affect alternative primary targets (Ura7 and
Ade6, respectively), possessing an aminotransferase ac-
tivity in common with Gua1. Collectively, these results
highlight the extensive level of information achieved by1164 Chemistry & Biology 14, 1163–1175, October 2007 ª2007monitoring chemical-induced HI across a global target
set and in the context of the cellular milieu.
RESULTS
C. albicans Fitness Test MOA Analysis of
ECC1385, Mycophenolic Acid, and Mizoribine
Compound ECC1385 (Figure 1A) was identified as a syn-
thetic molecule displaying potent activity against several
pathogenic fungi, including multipleCandida spp.,C. neo-
formans, and A. fumigatus (Table S1). To elucidate itsElsevier Ltd All rights reserved
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Nucleotide Synthesis Inhibitors in C. albicansFigure 2. Outline of the Purine Metabolism and the Salvage Pathway
Proteins involved in the Salvage Pathway (SP) are underlined, and all C. albicans genes with orf19 designations are provided. MPA, mycophenolic
acid; Ade, adenine; Gua, guanine; Hyp, hypoxanthine; Xan, xanthine; PRPP, 5-phosphoribosyl-1-pyrophosphate; ADP, adenosine 50-diphosphate;
AMP, adenosine 50-monophosphate; IMP, inosine 50-monophosphate; XMP, xanthine 50-monophosphate; GMP, guanine 50-monophosphate; GDP,
guanine 50-diphosphate; ext., extracellular medium; int., intracellular.MOA, compound-induced HI was surveyed in the CaFT
assay, which includes 2868 heterozygous deletion strains
and represents approximately 45% genome coverage
[11]. CaFT analysis revealed a single heterozygote strain
corresponding to GUA1 as reproducibly hypersensitive
to ECC1385 over all inhibitory concentrations tested
(Figure 1B). MIC determinations of individual strains con-
firmed this hypersensitivity to ECC1385 (Figure 1C).
GUA1 is predicted to encode GMPS, which catalyzes
the final step in the synthesis of GMP, converting XMP to
GMP (Figure 2). A comparative analysis of GMPS proteins
reveals that bacterial and fungal enzymes have signifi-
cantly diverged from their mammalian counterparts (see
Discussion and Figure S1 in the Supplemental Data avail-
able with this article online). Moreover, the ECC1385 anti-
microbial potency noticeably correlates with the degree of
similarity displayed by Gua1, particularly among Candida
spp. (Table S1 and Figure S1). These observations sug-
gest that ECC1385 targets GMPS and thus may represent
a broad-spectrum antifungal compound with potential
selectivity.
To test this possibility, we first examined the CaFT pro-
files of compounds known to affect GMP synthesis. Such
studies serve to verify the robustness of the CaFT assay in
determining the MOA of GMP pathway inhibitors. Myco-Chemistry & Biology 14, 1163–1phenolic acid (MPA) and mizoribine (MZ) are known to
affect guanine nucleotide metabolism by inhibiting Imd3,
an IMP dehydrogenase that catalyzes the oxidation of IMP
to XMP (the substrate for Gua1) [17–19]. Indeed, the IMD3
heterozygote was identified by CaFT analysis as the most
hypersensitive strain to MPA treatment (Figure 1B). Addi-
tional MPA hypersensitive heterozygous strains identified
include TPO1, which corresponds to an efflux pump pre-
viously reported to function in MPA detoxification [20],
as well as ADK1 and ADE12, while AMD1 displayed re-
sistance. Significantly, these genes all participate in the
conversion of IMP to ADP (Figure 2); ADK1 and ADE12 en-
code adenylate kinase and adenylosuccinate synthetase,
respectively, while AMD1 encodes AMP deaminase. MIC
determinations with these heterozygotes in isolation con-
firmed their altered sensitivity to MPA (Figure 1D). CaFT
analysis also confirmed the IMD3 heterozygote strain to
be markedly hypersensitive to MZ (Figure 1B). However,
two MZ resistant heterozygotes also provided insight
into this compound’s metabolism and import. ADO1 en-
codes an adenosine kinase required to phosphorylateMZ,
thereby converting the prodrug to its active form [21],
while NNT1 encodes a nucleoside transporter, which is
likely responsible for the uptake of MZ (see Discussion).
Therefore, CaFT profiles for known inhibitors of this175, October 2007 ª2007 Elsevier Ltd All rights reserved 1165
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Nucleotide Synthesis Inhibitors in C. albicansFigure 3. Guanine Suppression of the Growth Inhibitory Effects of ECC1385 and MPA
(A) Dose response of GUA1 and HIS3 heterozygous strains to ECC1385 and suppression by guanine (G, 125 mM) versus adenine (A, 1.25 mM).
(B) Dose response of IMD3 and HIS3 heterozygote strains to MPA and suppression by guanine (125 mM) versus adenine (1.25 mM).
(C) Dose response of the HIS3 heterozygote control and a homozygous deletion fcy2/ strain to ECC1385 and effect of guanine (125 mM).
(D) Dose response of pTet-GUA1 and pTet-HIS3 conditional mutants to ECC1385. Strains were examined under inducing (no tetracycline) or repres-
sing conditions (50 mg/ml tetracycline) either in the presence or absence of guanine (125 mM).pathway faithfully reflect their known MOA and support
the utility of using this approach to suggest a MOA for
ECC1385.
Exogenous Guanine Suppresses ECC1385
and MPA
CaFT profiles suggest MPA and MZ are mechanistically
distinct from ECC1385, inhibiting sequential enzymes in
the conversion of IMP to GMP, yet all three compounds
inhibit a common pathway. We predicted that the growth
inhibitory effects of these compounds should be signifi-
cantly reversed provided: (1) cells are supplemented an
exogenous source of guanine, and (2) a functional Salvage
Pathway (SP) is available to uptake guanine. Exogenous
guanine significantly suppressed the inhibitory activity of
ECC1385 at % MIC levels (<4 mg/ml) for C. albicans1166 Chemistry & Biology 14, 1163–1175, October 2007 ª2007(Figure 3A), and MPA was fully suppressed up to the high-
est soluble concentration (%64 mg/ml) (Figure 3B). In con-
trast, adenine failed to suppress the inhibitory activity of
either ECC1385 or MPA (Figures 3A and 3B).
We next examined whether the guanine-specific sup-
pression of ECC1385 requires a functional SP. The first
step of this pathway involves the uptake of guanine or ad-
enine and is mediated by the permease Fcy2 [22]. Unlike
wild-type cells, an fcy2 homozygote deletion mutant dis-
played no altered sensitivity to ECC1385 when provided
exogenous guanine (Figure 3C), demonstrating its abso-
lute requirement in the guanine-dependent suppression
of ECC1385. Similarly, a tetracycline regulatable mutant
of HPT1 [15] that is unable to convert imported guanine
to GMP was unaffected in its sensitivity to ECC1385 (or
MPA), despite the presence of guanine in the mediumElsevier Ltd All rights reserved
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version to GMP are both required to suppress the growth
inhibitory activity of ECC1385.
To further examine the susceptibility of GUA1 mutant
strains to ECC1385, a C. albicans pTet-GUA1 conditional
expression mutant was constructed by deleting one allele
and placing the second one under the control of the tetra-
cycline regulatable promoter [15]. As expected, the addi-
tion of a suppressing concentration of tetracycline to the
pTet-GUA1 strain markedly impaired growth (Figure 3D,
closed triangles), while the simultaneous supplementation
with guanine fully reversed this phenotype and paralleled
wild-type susceptibility to ECC1385 (Figure 3D, closed di-
amonds). Intriguingly, the pTet-GUA1 strain also displayed
partial resistance to ECC1385 under nonrepressing con-
ditions (Figure 3D, open triangles), presumably due to in-
trinsic GUA1 overexpression caused by the tetracycline
promoter. This reduced susceptibility was enhanced by
the addition of guanine (Figure 3D, open diamonds). Col-
lectively, these results provide independent evidence that
ECC1385 inhibits theGua1-mediated step in theGMPsyn-
thesis pathway to elicit its growth inhibitory effect.
ECC1385 Inhibits GMP Synthase Activity In Vitro
GMPS contains two functional domains, an amidotransfer-
ase domain that removes an amino group from glutamine
and a synthase domain responsible for the amination of
XMP to yield GMP. Alternatively, GMPS can also use free





To evaluate whether ECC1385 directly inhibits GMPS
enzymatic activity, an in vitro biochemical assay was per-
formed with extracts prepared from pTet-GUA1 cells
grown under nonrepressing conditions that are inferred
to overproduce Gua1 (see above and Figure 3D). To assay
GMPS activity, 14C-labeled XMP was used and the ap-
pearance of labeled GMP was monitored by thin-layer
chromatography (see Experimental Procedures). Whereas
mock-treated extracts converted XMP to GMP within 30
min, ECC1385 preincubation partially inhibited XMP con-
version at 1 mM and completely abolished it at R10 mM
(Figure 4A). GMPS activity was unaffected in control ex-
tracts treated with MPA (data not shown). Consistent
with the functional role of Gua1, extracts prepared from
the pTet-GUA1 strain grown under repressing conditions
(50 ug/ml tetracycline) in the presence of 0.75mMguanine
lacked any detectable GMPS activity (data not shown).
Therefore, ECC1385 inhibition of GMPS is a phenocopy
of the genetic depletion of Gua1.
GMPS inhibition by ECC1385 was next compared to
two previously described GMPS inhibitors, acivicin (ACI)Chemistry & Biology 14, 1163–1and 6-diazo-5-oxo-L-norleucine (DON). Both inhibitors
have been classified as glutamine antagonists that inhibit
glutamine-dependent amidotransferases [24–26]. When
C. albicans GMPS activity was assayed after preincubat-
ing the protein extract in the presence of each inhibitor
with XMP, ATP, and Mg2+ (reaction was started with
the addition of glutamine as the amino donor), ECC1385
(in vitro MIC of 10 mM) (Figure 4A, lane 8) showed a
3-fold greater potency than ACI or DON (MIC 30 mM
for both) (Figure 4A, lanes 14 and 19, respectively). How-
ever, when the GMPS assay was carried out using ammo-
nium sulfate (AS) as the amino donor, ACI was unable to
Figure 4. ECC1385, ACI, and DON Inhibit C. albicans In Vitro
GMP Synthase Activity
(A) Effect of preincubation with ECC1385, ACI, or DON, on the gluta-
mine-dependent GMPS activity. All components of the reaction mix
(with the exception of glutamine) were preincubated for 10 min at 21C
and the reaction started by the addition of 1 ml of 125 mM glutamine.
(B) Effect of preincubation with ECC1385, ACI, or DON, on the ammo-
nia-dependent GMPS activity. Reaction conditions were similar to (A),
with the exception that catalysis was started by the addition of 1 ml of 1
M (H4N)2SO4 (pH 7.5).
(C) Effect of glutamine on ECC1385, ACI, or DON, inhibitory capacity of
GMPS. All components of the reaction mix (with the exception of XMP)
were preincubated for 10 min at 21C, and the reaction started by the
addition of radiolabeled XMP. Standards: X, XMP; G, GMP (purified
14C-labeled nucleotides). Inhibitors were tested at the concentrations
indicated at the top of each panel (in mM).175, October 2007 ª2007 Elsevier Ltd All rights reserved 1167
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trations ashighas300mM(Figure 4B, lanes10–16); consis-
tent with this, ACI does not inhibit the AS-dependent
human GMPS activity [27]. ECC1385 inhibited GMP syn-
thesis to the same extent in the glutamine- and AS-depen-
dent catalytic reactions (Figures 4A and 4B, lanes 3–9),
while DON was slightly less potent in the AS-dependent
reaction (MIC 100 mM) (Figure 4B, lanes 17–22). To fur-
ther examine possible mechanistic differences between
these compounds, the GMPS assay was adjusted to in-
clude glutamine during preincubation and the reaction
started by the addition of labeled XMP. Since glutamine ef-
fectively competes with its antagonists, thereby decreas-
ing their potency, we reasoned that if ECC1385 does not
act as a glutamine antagonist, its potency should not be di-
minished under these conditions. Indeed, the ECC1385
MIC against GMPS was invariant (10 mM) (Figure 4C,
lane 8), while DON and ACI MICs were approximately 30
times greater (1000 mM) (Figure 4C, lanes 16 and 22, re-
spectively). These results suggest that ECC1385 does not
inhibitC. albicansGMPS activity in a manner analogous to
glutamine antagonists.
ECC1385, ACI, and DON Display Distinct
MOAs in Whole Cells
ECC1385, ACI, and DON all inhibit C. albicans GMPS
activity in vitro, yet display distinct substrate-dependent
activity. Moreover, ACI and DON are reported to inhibit
in vitro a family of enzymes that share a class I amidotrans-
ferase activity that is also common to GMPS [28], includ-
ing carbamyl phosphate synthetase, CTP synthetase, and
formyl-glycinamide ribonucleotide synthetase (FGAM
synthase) [24, 29]. Therefore, CaFT profiling was per-
formed to examine whether ACI and/or DON may have a
distinctMOA inwhole cells versus ECC1385. Interestingly,
the CaFT profile of DON revealed the ADE6 heterozygote
strain to be markedly hypersensitive to DON, whereas the
GUA1 heterozygote was not differentially sensitive. A sec-
ond unique aspect of the DON CaFT profile was the in-
creased resistance of the orf19.7506 heterozygote, which
corresponds to an uncharacterized gene exclusive to
Candida spp., but whose role in the MOA of DON is un-
known. MIC determinations of ADE6 and orf19.7506
heterozygotes confirmed their altered sensitivity to DON
(Figure S2A). CaFT profiling of ACI also failed to detect a
GUA1 heterozygote depletion; instead, the URA7 hetero-
zygote was identified as strikingly hypersensitive to ACI
(Figure 5, and also confirmed by MIC determinations,
Figure S2B). As ADE6 and URA7 encode FGAM synthase
and CTP synthase, respectively, and both enzymes pos-
sess class I amidotransferase activity, we speculate that
in C. albicans whole cells, the corresponding primary tar-
gets of DON and ACI are Ade6 and Ura7, rather than
GMPS.
To corroborate their alternative MOA in whole cells,
suppression of DON growth inhibitory activity was first
examined with nucleobase supplements. As predicted,
adenine partially suppressed the inhibitory activity of DON
(Figure S2C). Since DON also has inhibitory capacity1168 Chemistry & Biology 14, 1163–1175, October 2007 ª2007in vitro on other transaminases involved in nucleotide
synthesis (e.g., GMP synthase), the simultaneous addition
of guanine and adenine was tested but no improved sup-
pression was observed (data not shown). Similar tests
involving cytosine, cytidine, or CTP supplements to sup-
press the effect of ACI were not feasible as the C. albicans
pTet-URA7 strain grown under repressing conditions was
not suppressed under such conditions (Figure 6A), due ei-
ther to the inability of fungal cells to take upCTP or convert
cytosine to CTP [30].
Partial suppression of DON by adenine supplementa-
tion suggests that, in addition to Ade6, DON likely inhibits
a second target in whole cells. This was tested by reex-
amining DON in the CaFT with adenine added to the
medium. Under such conditions, instead of a noticeable
ADE6 heterozygote depletion, a dose-dependent URA7
heterozygote hypersensitivity was observed, as well as
continued orf19.7506 heterozygote resistance (Figure 5).
Therefore, although DON has been previously reported
in vitro to inhibit GMPS activity [24], CaFT profiling studies
that assess its effects globally andwithin the cellular milieu
emphasize a more complex MOA involving multiple ami-
dotransferases (Ade6 and Ura7) rather than Gua1.
GUA1 Is Essential for Virulence in C. albicans
and A. fumigatus
S. cerevisiae GUA1 is a conditional essential gene whose
function is not required in the presence of guanine pro-
vided the cell is competent to convert extracellular gua-
nine into GMP [31]. However, as S. cerevisiae is naturally
nonpathogenic, it is unclear whether gua1 loss-of-function
mutants would impair virulence of pathogenic fungi. To
test this possibility, we first examined the terminal pheno-
types of the C. albicans pTet-GUA1 strain as well as an
A. fumigatus GUA1 conditional mutant, constructed with
a nitrate-regulatable (NiiA) promoter replacement strategy
[32]. As expected, GUA1 was required for growth of both
pathogens under repressing conditions on minimal media
lacking guanine but dispensable when guanine was sup-
plemented to the medium (Figures 6A and 6B).
Importantly, phenotypes associated with pTet-GUA1
and pNiiA-GUA1 conditional mutants may be examined
in an animal model of infection, as their respective pro-
moters are efficiently repressed in vivo [15, 32]. In amurine
model of systemic candidiasis, mice (n = 15) were infected
with 106 cells of the C. albicans pTet-GUA1 strain, and
divided into three different regimes: (1) doxycycline (an
analog of tetracycline with superior pharmacokinetic
properties) supplemented to drinking water three days
prior to and throughout the infection time course (model-
ing a prophylactic treatment), (2) doxycycline supple-
mented to drinking water 2 days postinfection and
throughout the infection time course (modeling a systemic
treatment), and (3) no doxycycline added to the animal
drinking water (virulence control) (Figure 6C). All mice pre-
treated with doxycycline from the onset of infection sur-
vived and remained healthy over 22 days, whereas all con-
trol mice not administered the repressor succumbed to
infection within 11 days. Similarly, repression of GUA1Elsevier Ltd All rights reserved
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CaFT profiles identifyADE6 andURA7 as specifically hypersensitive heterozygotes to DON and ACI, respectively. Note that under conditions in which
DON growth inhibitory activity is partially suppressed by 0.5 mM adenine supplementation, URA7 heterozygote sensitivity is detected (see text for
details). MIC determinations verify all strain sensitivities predicted in CaFT profiles (Figure S2). Representative CaFT profiles of ECC1385 and
MPA are included to emphasize mechanistic differences between these compounds and DON or ACI.starting at 2 days postinfection, resulted in no mortality or
obvious morbidity. Therefore, although the C. albicans
pTet-GUA1 strain was fully virulent when GUA1 was in-
duced, its repression, even at later time points in the infec-
tion, ablated the normal virulence. All mice maintained on
either doxycycline regimes remained healthy even after
removing the repressor from their drinking water on day
22, until the experimental endpoint on day 36, implying
that the infection was significantly cleared during the
doxycycline treatment. Necropsy experiments across all
treatment groups confirmed that the fungal burden in
mouse kidneys was often reduced to the limit of detection
(Table 1).
Although the pNiiA-regulatable promoter cannot be
controlled in as elaborate amanner as the aforementioned
tetracycline promoter system, it is effectively repressed in
vivo due to sufficient ammonium (repressor) levels within
the host and can therefore be used to study possible viru-
lence phenotypes resulting from genetic inactivation [32].
Mice were immunocompromised with cyclophosphamide
and infected with 105 conidia derived from the A. fumiga-
tus pNiiA-GUA1 conditional mutant or the parental wild-
type control strain CEA10. Necropsies performed at day 1Chemistry & Biology 14, 1163–1postinfection on mice treated with CEA10 and pNiiA-
GUA1 strains confirmed that both groups harbored similar
infectious loads, from 3 to 73 103 conidia/g of kidney (Ta-
ble 1). CEA10 was fully virulent, with no mice surviving
past day 4. In contrast, the pNiiA-GUA1 conditional mu-
tant appeared completely avirulent (100% survival) over
the 21 day time course of the infection, with mice showing
no obvious signs of lethargy or morbidity (Figure 6D).
Moreover, necropsies on all surviving pNiiA-GUA1 infected
mice failed to detect A. fumigatus in the kidney. We con-
clude that, despite a demonstrated guanine-conditional
essentiality of GUA1 in both C. albicans and A. fumigatus,
neither pathogen is able to scavenge sufficient guanine,
and both are therefore avirulent in murine models of infec-
tion when lacking GUA1 function.
DISCUSSION
We have performed compound MOA studies by mon-
itoring chemical-induced haploinsufficiency within an
extensive C. albicans heterozygote strain set adapted
for screening in a fitness test format. The robustness of
this approach is demonstrated by examining known175, October 2007 ª2007 Elsevier Ltd All rights reserved 1169
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Nucleotide Synthesis Inhibitors in C. albicansFigure 6. GUA1 Is a Conditional Essential Gene Required for Virulence of C. albicans and A. fumigatus
(A) Growth effects of C. albicans tetracycline promoter replacement mutants for GUA1, CDR1 (control gene), ADE6, and URA7 (see text for details)
were examined on YPD at 30C for 2 days. Growth was compared to that observed under repressing conditions (100 mg/ml tetracycline) in the ab-
sence or presence of 125 mM guanine, 1.25 mM adenine, or 1.25 mM cytosine plus 1.25 mM cytidine (2Cs).
(B) Growth effects of an A. fumigatus NiiA promoter replacement mutant ofGUA1 versus the wild-type strain (CEA10) were compared under inducing
(AMMplus nitrate) or repressing (AMMplus ammonium) conditions at 37C for 2 days. Exogenous guanine (400 mM) fully suppressed the growth phe-
notype of pNiiA-GUA1 grown under repressing conditions.
(C) In vivo target validation ofC. albicans GUA1 in a murinemodel of infection. Mice were infected with 106 cells ofC. albicans pTet-GUA1 and divided
into three treatment groups: (), doxycycline provided starting 3 days before infection; (B), doxycycline treatment provided starting 2 days after the
infection; (D), sugar 5% (control). Twenty-one days postinfection (arrow), two mice from each group were taken for necropsy, and remaining mice
switched from doxycycline to water until day 35 postinfection, when two additional mice were taken for necropsy.
(D) In vivo validation of a pNiiA-GUA1 mutant in an immunocompromised murine model of systemic aspergillosis. Approximately 105 viable conidia
were injected into the tail vein of immunocompromised mice (five mice per group) and monitored for up to 22 days following infection. (B), pNiiA-
GUA1 strain; (), wild-type strain (CEA10).compounds classified as inhibiting various aspects of
de novo purine metabolism, as well as ECC1385, which
acts by inhibiting GMPS. In this approach, targets are
identified empirically by screening growth inhibitory com-
pounds of unknown MOA against a diversity of potential
targets. Consequently, target validation studies are per-
formed after chemical screening is completed and the
target demonstrated to be susceptible to chemical inhibi-
tion. Applying this approach, a hypothesis for the MOA of1170 Chemistry & Biology 14, 1163–1175, October 2007 ª200ECC1385 was established and verified by biochemical
and genetic assays consistent with GMPS being its pri-
mary target. Our work also extends the characterization
of GUA1, which encodes GMPS. GUA1 is a conditional
essential gene, required for normal growth of both C. albi-
cans and A. fumigatus, but dispensable in the presence of
a supplementary guanine source. Importantly, depletion
of GUA1 activity is not suppressed in a host environment,
as GUA1 conditional mutants of both pathogens are7 Elsevier Ltd All rights reserved
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Kidney Fungal Burden Postinfection with C. albicans pTet-GUA1
Treatment Mouse After 21 Days (CFU/g Kidney) Mouse After 35 Days (CFU/g Kidney)
DOX-3 A *** C 6.0 3 104
B 7.3 3 104 D 4.2 3 104
DOX+2 A 1.1 3 106 C ***
B *** D 6.8 3 106
Necropsy Results at Day 1 Postinfection with A. fumigatus Strains
Strain Mouse Conidia/g Kidney
pNii-GUA1 A 4.2 3 103
B 4.3 3 103
C 7.1 3 103
CEA10 A 3.6 3 103
B 3.0 3 103
Triple asterisks represent less than 1 3 104. CFU, colony forming units.avirulent under repressing conditions in murine models of
infection. Thus, GUA1 represents an unexpected antifun-
gal therapeutic target.
Like GUA1, other genes required for prototrophy of
intermediary metabolism function are implicated in micro-
bial pathogenesis. In uracil biosynthesis, URA3 (orotidine
50-phosphate decarboxylase) is required for pathogenicity
ofC. albicans and A. fumigatus [33, 34]. Mutants defective
in either adenine (ade2) or heme (hem3) biosynthesis are
also avirulent in C. albicans [33] and pabaA mutants (de-
fective in p-amino-benzoic acid biosynthesis) are avirulent
inA. fumigatus [35]. In addition, ura7 and ade6mutants are
avirulent in a candidiasis model of infection (Figures S3A
and S3B). In contrast, amino acid biosynthetic genes, in-
cluding HIS1, ARG4, and LEU2 [36], as well as MET2,
MET16, TRP5, HIS7, THR4, and LYS2 (our unpublished
data) do not noticeably attenuate C. albicans pathogene-
sis when mutated. Presumably, these differences reflect
the pathogen’s proficiency to scavenge metabolites and
the requirement that sufficient levels of such metabolites
exist in the host environment.
A comparative analysis of GUA1 across prokaryotes
and eukaryotes supports its consideration as an antifungal
target. Although Gua1 is broadly conserved, it has signif-
icantly diverged among fungi, plants, bacteria, and meta-
zoans (Figure S1). Fungal and plant Gua1 orthologs ap-
pear most closely related, consistent with their common
ancestry, whereas mammalian orthologs are most di-
verged. Interestingly, the fungal pathogens, including C.
albicans, C. glabrata, and A. fumigatus all share R65%
identity among one another and%38% identity to human
Gua1. A similar level of divergence exists between human
and fungal Erg11 (39%), the target of azole-based antifun-
gal therapeutics [37]. Therefore, Gua1-specific inhibitory
compounds could display similar fungal spectrum and se-
lectivity. Moreover, as recent bioinformatics-based efforts
to catalog broad spectrum antifungal targets [38, 39] have
excluded conditional essential genes (including GUA1),Chemistry & Biology 14, 1163–11their inclusion should broaden the complete antifungal tar-
get set if validated experimentally.
Our work demonstrates ECC1385 to be a novel Gua1
inhibitor with improved potency versus the previously re-
ported GMPS inhibitors, ACI or DON. Moreover, unlike
the latter compounds, only ECC1385 displays an in vitro
potency that correlates with its growth inhibitory activity
against whole cells. As ECC1385 is structurally unrelated
to glutamine antagonists such as ACI and DON, its spec-
ificity and potency may result from inhibiting the GMPS
activity rather than the amidotransferase activity of Gua1.
In support of this possibility, unlike glutamine antagonists
whose amidotransferase inhibitory activity is sensitive to
whether glutamine or ammonia substrates is provided
[27], no such substrate selectivity compromises ECC1385
inhibition of Gua1 (Figures 4A–4C). Inhibitors that de-
crease GMP levels serve as useful chemical reagents to
study purine metabolism and/or as tools in molecular biol-
ogy [40]. However, ECC1385 failed to exhibit efficacy at
12.5 and 25 mg/kg and displayed toxicity at 50 mg/kg
in a murine model of candidiasis (data not shown). Thus,
chemical improvements to ECC1385 are required to ad-
vance its therapeutic potential. Alternatively, target-based
biochemical and/or whole-cell screens [38, 41, 42] could
beperformed to uncover newGMPS inhibitorswith greater
intrinsic efficacy. As both MZ and MPA are clinically used
as immunomodulators, whose immunosuppression ef-
fects result from preferential GMP depletions in T cells
and B cells [43], specific inhibitors of the human GMPS
may also possess therapeutic potential.
Chemically induced HI, surveyed across extensive ge-
nome coverage, identifies important aspects of a com-
pound’s MOA [7, 11]. For example, although an IMD3 het-
erozygote is known to be hypersensitive to MPA [20], its
mechanistic significance is emphasized when compared
more globally across the genome. Here, in addition to
identifying Imd3 as the primary target of MPA, ADE12
and ADK1 heterozygote hypersensitivity and AMD175, October 2007 ª2007 Elsevier Ltd All rights reserved 1171
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metabolic pathway targeted by the drug. Based on their
phenotypes, it appears that as IMP levels increase in re-
sponse to the chemical inhibition of Imd3, efficient shunt-
ing of IMP to ADP (Ade12 and Adk1) seems to partially
buffer the cell from MPA, whereas conversion of AMP to
IMP (Amd1) enhances its toxicity (Figure 2). Presumably,
this reflects a fitness advantage for cells best able to res-
cue some benefit (namely ADP production) under condi-
tions where all cells incur the same metabolic cost of ac-
cumulating IMP, which can not be converted to GMP.
Imd3 was also correctly identified as the drug target of
MZ, but in addition, the resistance of a ADO1 heterozy-
gote reflects the in vivo activation of MZ; namely, its phos-
phorylation by adenosine kinase to convert it from a pro-
drug to its active form [21]. Drug import and efflux
mechanisms for both drugs were also identified. Hyper-
sensitivity of a TPO1 heterozygote is congruent with its re-
ported role in the efflux of MPA [20]. NNT1 heterozygote
resistance to MZ likely reflects its reported function as
a nucleoside permease [11, 44], as MZ is an imidazole-
based nucleoside. Recently, it was demonstrated that C.
albicans sensitivity to MZ is suppressed by guanine and
guanosine but, unexpectedly, also by uridine (but not cy-
tidine) [19]; the authors speculate this could be due to
competition for a common transporter. Our work indicates
this transporter is likely Nnt1, as it possesses transport
specificity for these nucleosides and their analogs [44]
and is resistant to MZ when mutated.
MPA was first identified in 1896, making it one of the
earliest natural products discovered, yet its MOA and po-
tential pharmacological properties continue to be widely
investigated [43]. Recently, a study evaluatedMPA effects
across a collection of 4,787 yeast haploid knockout mu-
tants [18]. Surprisingly, over 100 genes affecting MPA re-
sistance were uncovered across a wide spectrum of cellu-
lar functions, but core aspects of IMP metabolism we
identify were not reported. Although we cannot rule out
species-specific MPA effects, it is more likely that this re-
flects differences between the two assays. We speculate
that chemically induced HI combined with stringent
strain-specific errormodels (which statistically deprioritize
nonspecific drug sensitivities) effectively resolve a com-
pound’s primary MOA over more complex or indirect
effects. However, potential complications or liabilities as-
sociated with this specific approach include the absence
of full-genome coverage in the present assay, allelic poly-
morphisms and/or posttranscriptional regulation of partic-
ular genes, whichmay confound the haploresponsiveness
of some strains, as well as the fidelity of barcodes used to
monitor strain fitness in a microarray format [7–9, 11].
CaFT profiling of ECC1385 did not reveal additional
aspects of its MOA other than a chemical genetic relation-
ship withGUA1. Guanine-based suppression of ECC1385
supports the view that Gua1 is the drug target rather than it
playing an indirect role such asmetabolizing or detoxifying
ECC1385. Moreover, ECC1385 inhibition of GMPS is
a phenocopy of a pTet-GUA1 conditional mutant, which
similarly abolishes GMPS activity under repressing condi-1172 Chemistry & Biology 14, 1163–1175, October 2007 ª200tions. However, ECC1385 may affect an additional tar-
get(s), as suggested by the inability of guanine to fully sup-
press its inhibitory effects at super-MIC levels. Further
analysis of ECC1385 MOA in the CaFT in the presence
of guanine failed to identify any other significantly affected
strain (see Supplemental Data and Figure S4A). Therefore,
if ECC1385 affects a secondary target, its corresponding
heterozygous strain is either absent from the screening
pool or unresponsive in a haploinsufficiency-based read-
out.
Intriguingly, both ACI and DON inhibited C. albicans
GMPS activity in vitro (Figure 4), yet neither compound af-
fected the GUA1 heterozygote in the CaFT. Instead, we
hypothesize their primary targets in whole cells be Ura7
and Ade6, respectively. Consistent with this view, each
enzyme possesses a common amidotransferase activity,
yet only Gua1 has a GMPS activity. Moreover, ACI and
DON are glutamine antagonists reported to inhibit amido-
transferases by blocking their ability to use glutamine
as substrate, rather than directly inhibiting GMPS activity
[27]. Our work emphasizes a promiscuity of glutamine an-
tagonists, most strikingly exemplified by the CaFT profile
of DON in combination with adenine; when suppression
of DON’s putative primary target (ADE6) is achieved,
a dose-dependent hypersensitivity of the URA7 heterozy-
gote could be observed. Consistent with our results, an
analysis of the metabolic intermediates that accumulate
during DON treatment in mouse leukemia cells also impli-
cates Ade6 and Ura7 as likely targets of this drug [29]. Es-
tablishing robust correlations between a compound’s
MOA based on in vitro versus whole cell activity remains
an important challenge; particularly in caseswhere the tar-
get is a member of a large functionally related protein fam-
ily, such as amidotransferases or protein kinases [45]. In
such cases, global haploinsufficiency-basedMOA studies
may provide a general means to resolving the primary tar-
get within a cellular milieu from secondary targets also
inhibited in vitro but of less physiological relevance to
the inhibitor’s MOA.
SIGNIFICANCE
Identifying new drug targets and their cognate inhibi-
tors remain a significant challenge to the development
of novel antifungal therapeutics. To address these is-
sues, we have employed a genomics-based approach
applied in the principal fungal pathogen, C. albicans,
to study the MOA of a novel antifungal compound,
ECC1385. Examining its growth inhibitory effect among
2900 C. albicans heterozygous deletion mutants, we
identify the GUA1 heterozygote as uniquely hypersen-
sitive to this compound. We demonstrate by genetic
and biochemical means thatGUA1 encodes GMP syn-
thase and that ECC1385 is a potent and specific in-
hibitor of GMP synthase activity. Unlike the previously
reported GMP synthase inhibitors acivicin and DON,
only ECC1385 displays a MOA that correlates both
in vitro and in whole cells. Further, by examining
chemically induced haploinsufficiency produced by7 Elsevier Ltd All rights reserved
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preceding enzymatic step in GMP synthesis carried
out by Imd3, we highlight additional MOA information
pertinent to the uptake, efflux, and metabolism of
these drugs. These findings illustrate the capacity to
study drug MOA in the context of living cells to gain
mechanistic insights that may be tested by biochemi-
cal and/or genetic means. Finally, by determining the
growth inhibitory MOA of ECC1385 and genetically in-
activating its target, we demonstrate GUA1 to be es-
sential for C. albicans and A. fumigatus virulence,
thus illustrating how a chemical probe may be used
to identify an unanticipated antifungal drug target.
EXPERIMENTAL PROCEDURES
Chemicals and Reagents
ACI, DON, MZ, MPA, protease inhibitor cocktail for fungal extracts
(PICFE), amino acids, nucleotide bases, and all buffers and chemicals,
except when particularly indicated, were purchased from Sigma-
Aldrich. XMP was purchased from Fluka BioChemika (cat. 95550).
[8-14C]-labeled XMP and GMP (specific activities 50–60 Ci/mol) were
purchased fromMoravekBiochemicals. Plastic-backed,polyethylenei-
mine-cellulose-covered, thin-layer chromatography plates (PEI-TLC),
PolygramCEL300PEI (cat. #801-053)werepurchased fromMacherey-
Nagel. ECC1385 (CAS name: a,a-dimethyl-4-[1,1,2,2-tetrafluoro-2-(4-
methylphenyl)ethyl]-benzenemethanamine hydrochloride) was identi-
fiedwithin the corporate synthetic compound library and resynthesized
internally.
C. albicans Fitness Test and Strain Collection
Heterozygote and tetracycline-regulatable expression strains de-
scribed in this work were constructed as described in [15] and are
available for noncommercial use to academic researchers following
the standard Merck Material Transfer Agreement (MTA) and clearance
procedures. For a complete description of genes comprising the het-
erozygote strain set, as well as technical aspects of theC. albicans Fit-
ness Test, see [11]. Although we are unable to provide the complete
heterozygote strain set at this time, we invite academic researchers
to contact us regarding possible collaborations related toMOA studies
of bioactive compound(s) of mutual interest. Following an MTA agree-
ment executed by both parties, such compounds would be screened
by Fitness Test analysis and results communicated back to the collab-
orator.
Protein Extracts Preparation
Candida albicans strain pTet-GUA1, allowing tetracycline-repressible
Gua1 expression was separately grown either in YPD (nonrepressive
conditions), or YPD containing 50 ug/ml tetracycline, plus 0.75 mM
guanine (repressing conditions). Cells were harvested at an OD600
2 by centrifugation (10 min, 4C, 3,0003 g), and processed at a con-
stant temperature of 0C to 4C. 1,600 ODs of cells (fresh weight
3.5 g) were washed once with 50 ml of lysis buffer (50 mMNa HEPES
[pH 7.3], 10mM2-mercaptoethanol [2-ME], 2mMEDTA) and collected
as indicated above. Washed cells were then resuspended in 15 ml of
lysis buffer containing 2 mM phenylmethylsulfonylfluoride (PMSF)
plus PICFE and disrupted in a bead beater (0.5 mm glass beads).
The homogenate was removed, lysis buffer was added to complete
a final volume of 50 ml, and cell debris were eliminated by centrifuga-
tion (15 min, 4C, 3,000 3 g). The supernatant was kept, and the pro-
tein fraction precipitating at 80% saturation of ammonium sulfate was
obtained by adding 28 g of ammonium sulfate crystals. After centrifug-
ing for 15min, at 3,0003 g, the pellet was resuspended in 18ml of lysis
buffer and dialysed twice against 4 l of 10 mM Na HEPES (pH 7.3),
5 mM 2-ME, 0.1 mM EDTA, at 4C. After dialysis, antipain, pepstatin,
and leupeptin were added to the dialysate to reach a final concentra-Chemistry & Biology 14, 1163–tion of 1 ug/ml, PMSF to reach 0.2mM, and KCl to 100mM. After these
additions, the dialysate was cleared (5 min, 4C, 16,000 3 g) and the
supernatant (27 ml) concentrated by centrifugation in Millipore Ami-
con Ultra 4 units, aliquoted and frozen at80C (protein concentration
10 mg/ml); this fraction with <50 uM ammonium sulfate was named
‘‘AS-2D’’ and used as the source of GMPS activity in all the experi-
ments performed.
GMP Synthase Activity Assay
Protein extracts were assayed for GMPS activity at 30C for 30 min, in
a final volume of 25 ml containing: 50 mM Na HEPES (pH 8.2), 1 mM
ATP, 4 mM MgCl2, 0.1 mM DTT, 5 mM glutamine (replaced by 40
mM [H4N]2SO4 when indicated), 0.1 mM EDTA, 0.3 mM
14C-XMP
(13.3 Ci/mol), and 40 ug of protein (fraction AS-2D). Reactions were
stopped by transferring 6 ml aliquots to 24 ml of 1.25 M formic acid,
incubated on ice for 15 min, and centrifuged 10 min at 16,000 3 g to
pellet the denatured proteins from the soluble nucleotides. 20 ml of
these supernatants were transferred into 4.8 ml of 50% triethanolamine
for neutralization; 2 ml of this solution were spotted on PEI-TLC plates
and run on 0.75 M Tris-HCl (pH 8.0) (solvent Ta) [46]. After chromatog-
raphy, TLC plates were dried and exposed to radiographic film.
C. albicans and A. fumigatus Virulence Studies
C. albicans strains were grown overnight at 30C in YEPD, washed
twice, and resuspended inwater at a final concentration of 107 cells/ml.
Three groups of male ICR mice (five or six mice in each group) were
infected by tail-vein injection (106 cells per mouse): with one group
(Dox-3) receiving the doxycyline treatment 3 days prior to infection,
one group (Dox +2) receiving the doxycycline 2 days after infection,
and the control group, which remained on 5%sucrosewithout doxycy-
line for the duration of the experiment. Doxycycline was administered
orally in the drinking water ad libitum (2 mg/ml, in a 5% sucrose solu-
tion). At 21 days postinfection, two mice from each group were taken
for necropsy; remaining mice were switched to water, and survival
monitored for additional 2weeks,with additional necropsies performed
at 35 days postinfection.
A pNiiA-GUA1 conditional promoter replacement mutant of A. fumi-
gatus was constructed with the nitrogen-regulatable NiiA promoter,
and its virulence, and that of the wild-type CEA10, were assessed in
an immunocompromised murine model for systemic infection [32].
Briefly, CD-1 mice were rendered immunocompromised by treatment
with cyclophosphamide and infected by tail vein injection with 105 vi-
able Aspergillus conidia. Mice were kept immunocompromised and
monitored for survival up to a maximum of 22 days. All experiments
were performed according to the National Institutes of Health guide-
lines for the ethical treatment of animals.
Supplemental Data
Supplemental Data, including four figures, one table, and a spread-
sheet containing all the z scores obtained in the Fitness Test analyses,
are available online at http://www.chembiol.com/cgi/content/full/
14/10/1163/DC1/.
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